Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Bladder Cancer

  Free Subscription


Articles published in Cancer Res

Retrieve available abstracts of 14 articles:
HTML format
Text format



Single Articles


    May 2018
  1. CHEN A, Fu G, Xu Z, Sun Y, et al
    Detection of Bladder Cancer Via Microfluidic Immunoassay and Single-Cell DNA Copy Number Alteration Analysis of Captured Urinary Exfoliated Tumor Cells.
    Cancer Res. 2018 May 22. pii: 0008-5472.CAN-17-2615.
    PubMed     Text format     Abstract available


    February 2018
  2. DAIZUMOTO K, Yoshimaru T, Matsushita Y, Fukawa T, et al
    A DDX31/mutant-p53/EGFR axis promotes multistep progression of muscle invasive bladder cancer.
    Cancer Res. 2018 Feb 13. pii: 0008-5472.CAN-17-2528.
    PubMed     Text format     Abstract available


    September 2017
  3. GOLDSTEIN JT, Berger AC, Shih J, Duke FF, et al
    Genomic activation of PPARG reveals a candidate therapeutic axis in bladder cancer.
    Cancer Res. 2017 Sep 18. pii: canres.1701.2017.
    PubMed     Text format     Abstract available


  4. DUEX JE, Owens C, Chauca-Diaz A, Dancik GM, et al
    Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis.
    Cancer Res. 2017;77:4858-4867.
    PubMed     Text format     Abstract available


    April 2017
  5. VAN KAMPEN JGM, van Hooij O, Jansen CF, Smit FP, et al
    miRNA-520f Reverses Epithelial-to-Mesenchymal Transition by Targeting ADAM9 and TGFBR2.
    Cancer Res. 2017;77:2008-2017.
    PubMed     Text format     Abstract available


    March 2017
  6. NICHOLSON J, Jevons S, Groselj B, Ellermann S, et al
    E3 ligase cIAP2 mediates downregulation of MRE11 and radiosensitization in response to HDAC inhibition in bladder cancer.
    Cancer Res. 2017 Mar 31. pii: canres.3232.2016.
    PubMed     Text format     Abstract available


    February 2017
  7. MIAO L, Liu Q, Lin CM, Luo C, et al
    Targeting Tumor-Associated Fibroblasts for Therapeutic Delivery in Desmoplastic Tumors.
    Cancer Res. 2017;77:719-731.
    PubMed     Text format     Abstract available


    January 2017
  8. OWCZAREK TB, Kobayashi T, Ramirez R, Rong L, et al
    ARF confers a context-dependent response to chemotherapy in muscle invasive bladder cancer.
    Cancer Res. 2017 Jan 12. pii: canres.2621.2016.
    PubMed     Text format     Abstract available


    August 2016

  9. Correction: ATF3 Suppresses Metastasis of Bladder Cancer by Regulating Gelsolin-Mediated Remodeling of the Actin Cytoskeleton.
    Cancer Res. 2016;76:4592.
    PubMed     Text format    


    March 2016
  10. WANG M, Li Z, Chu H, Lv Q, et al
    Genome-Wide Association Study of Bladder Cancer in a Chinese Cohort Reveals a New Susceptibility Locus at 5q12.3.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available


    December 2015
  11. LI C, Du Y, Yang Z, He L, et al
    GALNT1-mediated glycosylation and activation of sonic hedgehog signaling maintains the self-renewal and tumor-initiating capacity of bladder cancer stem cells.
    Cancer Res. 2015 Dec 16. pii: canres.2309.2015.
    PubMed     Text format     Abstract available


    October 2015
  12. PALMBOS PL, Wang L, Yang H, Wang Y, et al
    ATDC/TRIM29 drives invasive bladder cancer formation through microRNA-mediated and epigenetic mechanisms.
    Cancer Res. 2015 Oct 15. pii: canres.0603.2015.
    PubMed     Text format     Abstract available


  13. REMY E, Rebouissou S, Chaouiya C, Zinovyev A, et al
    A Modeling Approach to Explain Mutually Exclusive and Co-Occurring Genetic Alterations in Bladder Tumorigenesis.
    Cancer Res. 2015;75:4042-52.
    PubMed     Text format     Abstract available


    May 2015
  14. HE F, Melamed J, Tang MS, Huang C, et al
    Oncogenic HRAS Activates Epithelial-to-Mesenchymal Transition and Confers Stemness to p53-Deficient Urothelial Cells to Drive Muscle Invasion of Basal Subtype Carcinomas.
    Cancer Res. 2015;75:2017-28.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: